GlobeImmune Announces Updates
17 nov. 2016 17h49 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 17, 2016) - GlobeImmune, Inc. today provided an update on the Company's business:Gilead Sciences, Inc. has terminated the collaboration and license agreement...
GlobeImmune Announces Delisting and Deregistration of Common Stock
05 juil. 2016 16h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - July 05, 2016) - GlobeImmune, Inc. (NASDAQ: GBIM) On June 30, 2016, the board of directors (the "Board") of GlobeImmune, Inc. (the "Company") made a determination to...
GlobeImmune Announces Updates and Financial Results for First Quarter 2016
12 mai 2016 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - May 12, 2016) -
GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for...
GlobeImmune Announces Updates and Financial Results for Full Year 2015
16 mars 2016 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - March 16, 2016) -
GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for...
GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights
13 nov. 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - November 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights
14 août 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 14, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options
13 août 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 13, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM), a biopharmaceutical company focused on developing products for the treatment of cancer and infectious diseases...
UPDATE - Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
04 août 2015 09h27 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 04, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to...
Celgene Exercises Early Option to Exclusively License GI-6207, a Novel Cancer Immunotherapy
04 août 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - August 04, 2015) - GlobeImmune, Inc. announced today that Celgene Corporation exercised its option under the 2009 Collaboration and Option Agreement to exclusively...
GlobeImmune Announces Evaluation of Strategic Alternatives and Corporate Restructuring
10 juin 2015 06h30 HE
|
GlobeImmune, Inc.
LOUISVILLE, CO--(Marketwired - June 10, 2015) - GlobeImmune, Inc. (NASDAQ: GBIM) today announced that it is evaluating strategic options for the company. In conjunction with this process, the Board...